


UNCOVER CANCER-SPECIFIC RNA ISOFORMS USING LONG-READ SEQUENCING


Novel biomarker and drug target discovery with the Iso-Seq[®] method

Alternative splicing affects protein function in cancer

Alternative splicing (AS) results in the generation of multiple RNA isoforms from a single gene, greatly increasing both transcriptomic and proteomic diversity. AS controls which introns are removed from pre-mRNAs and which exons are combined to form the final messenger RNA (mRNA).¹




Cancers display widespread RNA dysregulation, including alternative splicing of transcripts. These aberrant transcripts are often translated into cancer-specific proteins and have been shown to affect cancer initiation, progression, metastasis, and drug resistance.² For example, the *bcl-x* gene expresses two isoforms: long and short. The short isoform is expressed in normal tissues and regulates apoptosis. The long form is over-expressed in several cancers and blocks apoptosis, promotes cancer progression, and has been shown to cause resistance to chemotherapy.




Much of the cancer isoform repertoire remains unexplored

While it has been recently reported that cancer-specific isoforms can be used as novel prognostic biomarkers and serve as an untapped source of drug targets for immuno-oncology, the vast majority of cancer-specific isoforms remain unknown.^{3,4,5} With at least 95% of genes undergoing alternative splicing and producing multiple isoforms, much remains to be discovered.¹




Long-read sequencing provides significantly more robust isoform discovery power

Current short-read sequencing approaches rely on the alignment of sequenced fragments to a reference genome and are only able to reconstruct an estimated 20–40% of the transcriptome.^{6,7} A recent study showed that a short-read approach captured only a fraction (~41%) of truly novel isoforms identified by PacBio's long-read approach in cancer samples.¹ These intrinsic limitations in the discovery of novel isoforms likely underestimate the impact of isoforms in cancer and result in a partial view of the true biology of cancer.⁸



The Iso-Seq method utilizes long-read transcript sequencing to reliably capture full-length transcript isoforms without the need for computational assembly. PacBio's long-read RNA sequencing is also significantly less error-prone than other long-read sequencing technologies, offering more robust and accurate isoform discovery power.^{9,10} Future research will continue to explore the complex and mostly unexplored landscape of isoforms across cancer types.

The Iso-Seq method offers an end-to-end approach for isoform discovery



Library prep

SMRTbell® express kit



SMRT® sequencing

Sequel® IIe system



Data analysis

SMRT® Link



For a detailed protocol about RNA sequencing best practices visit pacb.com/RNAseq-bestpractices



Connect with PacBio for more info:
North America: nasales@pacb.com
South America: sasales@pacb.com
EMEA: emea@pacb.com
Asia Pacific: apsales@pacb.com

KEY REFERENCES

1. Pan, Q., et al. (2008) **Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.** *Nat Genet* 40, 1413–1415
2. Pan, Y., et al. (2021) **RNA dysregulation: An expanding source of cancer immunotherapy targets.** *Trends in Pharmacological Sciences*, 42(4), 217–312
3. Veiga, D., et al. (2022) **A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer.** *ScienceAdvances*, 8(3), doi: 10.1126/sciadv.abg6711.
4. Huang, K., et al. (2021) **Long-read transcriptome sequencing reveals abundant promoter diversity in distinct molecular subtypes of gastric cancer.** *Genome Biol*, 22(4), doi: org/10.1186/s13059-021-02261-x
5. Oka, M., et al. (2021) **Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer.** *Genome Biol* 22(9), <https://doi.org/10.1186/s13059-020-02240-8>
6. Tilgner, H., et al. (2014) **Defining a personal, allele-specific, and single-molecule long-read transcriptome.** *PNAS*, 111(27), <https://doi.org/10.1073/pnas.1400447111>
7. Sharon, D., et al. (2013) **A single-molecule long-read survey of the human transcriptome.** *Nat Biotechnol* 31, 1009–1014
8. Kahraman, A., et al. (2020) **Pathogenic impact of transcript isoform switching in 1,209 cancer samples covering 27 cancer types using an isoform-specific interaction network.** *Sci Rep* 10(14453), <https://doi.org/10.1038/s41598-020-71221-5>
9. Wyman, et al. (2019) **A technology-agnostic long-read analysis pipeline for transcriptome discovery and quantification.** *bioRxiv.* <https://doi.org/10.1101/672931>.
10. Al'Khafaji, et al. (2021) **High-throughput RNA isoform sequencing using programmable cDNA concatenation.** <https://www.biorxiv.org/content/10.1101/2021.10.01.462818v1>

Information in this document is subject to change without notice. PacBio assumes no responsibility for any errors or omissions in this document. Certain notices, terms, conditions, and/or use restrictions may pertain to your use of PacBio products and/or third party products. Refer to the applicable PacBio terms and conditions of sale and to the applicable license terms at <http://www.pacb.com/legal-and-trademarks/terms-and-conditions-of-sale/>. PacBio, the PacBio logo, SMRT, SMRTbell, Iso-Seq, and Sequel are trademarks of PacBio. All other trademarks are the sole property of their respective owners.

© 2022 PacBio. All rights reserved. Research use only. Not for use in diagnostic procedures.
102-193-690 REV01 07APR2022

PacBio